The serum, which contained antibodies against 2009 H1N1 influenza virus, protected the mice from death when they were later subjected to the 1918 H1N1 influenza virus. All of the experiments involving the 1918 virus were conducted under biosafety-level-3 conditions. More info about NIAID research on influenza is offered by ARTICLE: RA Medina et al. Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nature Communications DOI: 10.1038/ncomms1026 . WHO: Anthony S. Fauci, M.D., Director, NIAID Rachelle Salomon, Ph.D., program officer for preliminary research and diagnostics, Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, NIAID, are available for comment..The system comprises super-paramagnetic nanoparticles which were coupled with proprietary components that bind to lifeless and dying cells and cell particles. The resultant product selectively initiates dead-cell removal, emulating dead-cell clearance mechanisms which run in-vivo to keep tissues working optimally. This technology is step-changing, providing new opportunities to optimise cell development, culture and storage. The ability to selectively remove inhibitory or toxic dead cells using a simple and fast procedure results in radically improved cell populations; specifically, with regard to viability antibody/protein yield and consequent functional efficacy.amsbio.com/cliocell.aspx or contact AMSBIO on +44-1235-828200 / +1-949-768-8365 / email info@amsbio now.com.